Document Type: Research Articles
Medstar Antalya Hospital, Department of Radiation Oncology, Antalya, Turkey.
Bahçeşehir University School of Medicine, Department of Internal Medicine, Medical Oncology, Medicalpark Gaziantep Hospital, Gaziantep, Turkey.
Hacettepe University, Department of Radiation Oncology, Ankara, Turkey.
Suleyman Demirel University, Department of Radiation Oncology, Isparta, Turkey.
Medicalpark Gaziantep Hospital, Department of Biochemistry, Gaziantep, Turkey.
Bahçeşehir University School of Medicine, Department of Neurosurgery, Medicalpark Gaziantep Hospital, Gaziantep, Turkey.
Background: High-grade gliomas, with glioblastomas as the most frequently observed histologic subtype, are the most common primary brain tumours in adults. It is considered that inflammatory responses play a major role in malignancies, including tumour progression. This study aimed to determine the prognostic significance of the neutrophil to lymphocyte ratio (NLR) and the thrombocyte to lymphocyte ratio (PLR) as indicators of systemic inflammatory response (SIR) in glioblastoma patients. Methods: A total of 90 patients treated for glioblastoma were retrospectively evaluated. Absolute counts were used to generate NLR and PLR. A SIR was considered to be present with an NLR ≥5 and/or PLR ≥150. Results: Median follow-up time was 11.3 months (range: 1-70 months). The 1-year and 2-year overall survival rates were 55.2% and 19.5%, respectively. Univariate analysis showed that there was no correlation between overall survival and gender (p=0.184), comorbid disease (p = 0.30), clinical presentation (p = 0.884), or tumour lateralization (p = 0.159). Multivariate analysis showed that overall survival was significantly correlated with SIR based on NLR (HR: 2.41), and ECOG performance status (HR: 1.53). The prognostic factors that affected survival, other than SIR, were Eastern Cooperative Oncology Group (ECOG) performance status (p = 0.003), and tumour localization (p = 0.006). Conclusion: The present findings confirm that NLR based on peripheral blood counts prior to treatment can be used as a prognostic factor in patients with glioblastoma. Since tumour aggression increases and survival decreases as the NLR value rises, choice of treatment modality is facilitated for glioblastoma patients.